B2M Antibody

Product Specifications

Background

B2M Antibody: Beta2-microglobulin (B2M) is a principal component of the Major Histocompatibility Complex (MHC) class I molecule, a ternary membrane protein complex that displays fragments derived from proteolyzed cytosolic proteins on the surface of cells for recognition by the surveillance immune system (1,2) . B2M is involved in the presentation of peptide antigens to the immune system and plays a critically important role in immune system function (3) . It is expressed on nearly all nucleated cells and contains one Ig-like C1-type (immunoglobulin-like) domain (2,3) . Mutations in the Beta 2-microglobulin gene can enhance the progression of malignant melanoma and osteoarthropathy (4,5) .

NCBI Gene ID

567

Swiss Prot

P61769

Accession Number

NP_004039

Host

Rabbit

Reactivity

Human

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Immunology

Purification

B2M Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1220 - SK-N-SH Cell Lysate

Concentration

1 mg/mL

Homology

Predicted species reactivity based on immunogen sequence: Mouse: (83%), Rat: (83%)

Buffer

B2M Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

B2M antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year.

Fragment

IgG

Specificity

B2M antibody is human reactive.

Symbol

B2M

NCBI Official Name

Beta-2-microglobulin

NCBI Organism

Homo sapiens

Background Reference 01

Krangel MS, Orr HT, and Strominger JL. Assembly and maturation of HLA-A and HLA-B antigens in vivo. Cell 1979; 18:979-91.

Background Reference 02

Skjodt K, Welinder KG, Crone M, et al. Isolation and characterization of chicken and turkey beta 2-microglobulin. Mol. Immunol. 1986; 23:1301-9.

Background Reference 03

Ohashi K. Pathogenesis of beta2-microglobulin amyloidosis. Pathol. Int. 2001; 51:1-10.

Background Reference 04

Blum C, Graham A, Yousefzadeh M, et al. The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int. J. Oncol. 2008; 33:579-84.